Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
About Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative, molecularly-targeted, small-molecule therapies to address serious diseases, including oncology, obesity, and chronic liver diseases. Headquartered in Foster City, California, with additional operations in Shanghai, the company combines its expertise in medicinal chemistry and disease biology with a capital-efficient drug discovery model to advance its robust pipeline of therapeutic candidates.
The company's focus on small-molecule therapies enables the development of orally administered drugs, offering potential advantages in terms of patient convenience, scalability, and cost-effectiveness compared to injectable biologics. Terns’ pipeline includes multiple clinical-stage programs targeting significant unmet medical needs:
- TERN-701: An oral, allosteric BCR-ABL tyrosine kinase inhibitor (TKI) in development for chronic myeloid leukemia (CML). This novel therapy aims to overcome the limitations of traditional active-site TKIs, offering improved efficacy and safety profiles.
- TERN-601: A small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist designed for the treatment of obesity. This candidate demonstrates promising weight loss efficacy and a favorable tolerability profile, addressing common challenges associated with GLP-1 therapies.
- TERN-501: A thyroid hormone receptor-beta (THR-β) agonist targeting non-alcoholic steatohepatitis (NASH) and other liver diseases.
- TERN-800 Series: A preclinical program focused on glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for metabolic disorders.
Terns Pharmaceuticals operates within competitive and innovation-driven markets, where its focus on clinically validated targets and its ability to develop differentiated small-molecule therapies position it as a key player. The company’s strategic emphasis on both oncology and metabolic diseases reflects its commitment to addressing substantial unmet medical needs globally.
By leveraging its dual presence in the United States and China, Terns benefits from access to diverse patient populations, streamlined clinical development capabilities, and cost efficiencies. Its capital-efficient drug discovery model further supports the advancement of its pipeline while mitigating financial risks inherent to clinical-stage companies.
As a clinical-stage company, Terns Pharmaceuticals is reliant on the success of its ongoing and future clinical trials. Its ability to secure regulatory approvals and navigate competitive landscapes will be critical to its long-term success. However, its strong pipeline, innovative approach to drug development, and focus on addressing unmet medical needs provide a solid foundation for potential growth.
Terns Pharmaceuticals has appointed Dr. Ann E. Taylor to its Board of Directors. With over 35 years in drug development, including her tenure as Chief Medical Officer at AstraZeneca, Dr. Taylor is expected to bring valuable expertise to Terns, particularly in developing treatments for non-alcoholic steatohepatitis (NASH) and chronic liver diseases. Terns is known for its innovative therapeutic approaches, including a diverse pipeline featuring small-molecule therapies aimed at addressing NASH.
Terns Pharmaceuticals has completed patient enrollment for Part 1 of the AVIATION Trial, a Phase 1b study for TERN-201, a selective VAP-1 inhibitor targeting chronic liver inflammation and fibrosis in NASH patients. Preliminary top-line data is expected in 1Q 2022. The trial aims to assess the safety and tolerability of TERN-201 in comparison to a placebo over 12 weeks. TERN-201 has shown promise in preclinical studies, and the company received FDA Fast Track Designation for the treatment of NASH.
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focused on therapies for non-alcoholic steatohepatitis (NASH), announced upcoming presentations at key investor conferences in September 2021. The conferences include the 2021 Virtual Wells Fargo Healthcare Conference on September 9, the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and the Oppenheimer Fall Healthcare Summit on September 20. Investors can access live webcasts on Terns' investor relations page, with replays available for 30 days.
Terns Pharmaceuticals reported financial results for Q2 2021, achieving significant clinical milestones in its NASH pipeline. The company initiated the Phase 1b AVIATION Trial for TERN-201 and completed a multiple ascending dose portion of the TERN-501 trial. Cash reserves are strong at $185.1 million, projected to last until 2024. Top-line data from TERN-501 is expected in 4Q 2021 and from TERN-201 in 1H 2022. Despite a net loss of $10.7 million for the quarter, decreased R&D expenses show a positive trend for operating efficiency.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company, has announced its participation in two key healthcare conferences. Management will join a liver disease panel at the 2021 Wedbush PacGrow Healthcare Conference on August 10 at 2:20 PM ET. Additionally, Terns will present at the Canaccord Genuity 41st Annual Growth Conference on August 11 at 1:00 PM ET. Both events will be available via live webcast on Terns' investor relations page, with replays accessible for 30 days post-presentation.
Terns Pharmaceuticals initiated patient dosing for the AVIATION Trial, a Phase 1b study evaluating TERN-201, a selective VAP-1 inhibitor targeting chronic liver inflammation and fibrosis in NASH. This trial aims to assess the safety and efficacy of TERN-201 over a 12-week period, with preliminary data expected in 2022. TERN-201 demonstrated well-tolerated results in prior studies, showing significant potential in reducing liver inflammation. The drug's selective inhibition may complement other therapies in Terns’ portfolio.
Terns Pharmaceuticals reported positive results from the Phase 2a LIFT clinical trial of TERN-101, an FXR agonist for NASH treatment. The trial demonstrated no discontinuations due to adverse events, including pruritus, and significant improvements in corrected T1 (cT1), a liver inflammation and fibrosis marker. After 12 weeks, significant changes in cT1 were observed in the 10 mg and 15 mg groups compared to placebo. Terns plans a combination trial of TERN-101 with TERN-501 in early 2022, following these promising outcomes.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) announced a conference call to discuss new top-line data from the Phase 2a LIFT study evaluating TERN-101 in patients with non-alcoholic steatohepatitis (NASH). The call is scheduled for June 14, 2021, at 8:30 a.m. ET, with a live webcast available. Terns focuses on developing small-molecule therapies targeting NASH and chronic liver diseases, aiming to offer significant clinical benefits based on validated mechanisms of action. The details of the webcast and conference call are provided for interested stakeholders.
Terns Pharmaceuticals is set to present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 12:00 p.m. ET, followed by participation in the J.P. Morgan Biotech 2021 CEO Conference Call Series on May 25, 2021, at 1:00 p.m. ET. A live audio webcast will be accessible on the company’s investor page, with a 30-day archive available post-event. Terns specializes in developing small-molecule therapy candidates for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. For more details, visit their official website.
Terns Pharmaceuticals reported Q1 2021 financial results and corporate updates, highlighting advancements in their NASH clinical programs. With top-line data for the Phase 2a LIFT study of TERN-101 expected in June 2021, the company emphasizes the focus on safety and multiple non-invasive endpoints. The oversubscribed IPO raised $147 million, enhancing their financial position. R&D expenses rose to $8.7 million, while the net loss increased to $13.3 million from $9.2 million a year earlier. Cash reserves of $195.6 million are projected to support operations through 2024.
FAQ
What is the current stock price of Terns Pharmaceuticals (TERN)?
What is the market cap of Terns Pharmaceuticals (TERN)?
What does Terns Pharmaceuticals specialize in?
What is TERN-701?
How does Terns Pharmaceuticals differentiate itself in the biopharmaceutical industry?
What is the significance of TERN-601?
Where is Terns Pharmaceuticals headquartered?
What is the TERN-800 series?
What are the key therapeutic areas Terns Pharmaceuticals is targeting?
What is the company’s approach to drug development?
What challenges does Terns Pharmaceuticals face as a clinical-stage company?
How does Terns Pharmaceuticals leverage its dual presence in the U.S. and China?
